Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARS Pharmaceuticals, Inc.SPRY · Entity 883 | CHIEF MEDICAL OFFICER · 10% owner | January 02, 2026 | January 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARS Pharmaceuticals, Inc.
Report date January 02, 2026 · Filed January 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.49 · Expires 2036-01-01 | Direct | 240,000 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 240,000 · Balance 240,000 F1: The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2026. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.49 · Expires 2036-01-01 | IndirectBy Spouse | 875,000 |
Reported balance
After 2026-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 875,000 · Balance 875,000 F1: The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 16, 2024 Filed May 16, 2024 23:52 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 44,746 | $9.06 | $405,313.74 |
DisclosureSEC source: 0001415889-24-013388 · form4-05162024_110547.xml · nonDerivative · entry 6 Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020 Disclosed balance after: 1,597,447 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F8 · price: The weighted average sale price for the transaction reported was $9.0581, and the range of prices were between $9.00 and $9.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F3 · ownership.nature: The Reporting Person is trustee of the trust. Read SEC document |
| May 15, 2024 Filed May 16, 2024 23:52 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 2,766 | $9.04 | $25,005.47 |
DisclosureSEC source: 0001415889-24-013388 · form4-05162024_110547.xml · nonDerivative · entry 5 Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 Disclosed balance after: 1,792,849 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F7 · price: The weighted average sale price for the transaction report was $9.0403,and the range of prices were between $9.00 and $9.12. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares old at each separate price will be provided. F5 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of the trust. Read SEC document |
| May 15, 2024 Filed May 16, 2024 23:52 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 2,381 | $9.05 | $21,559.24 |
DisclosureSEC source: 0001415889-24-013388 · form4-05162024_110547.xml · nonDerivative · entry 4 Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020 Disclosed balance after: 1,642,193 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F6 · price: The weighted average sale price for the transaction report was $9.0547,and the range of prices were between $9.00 and $9.16. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares old at each separate price will be provided. F3 · ownership.nature: The Reporting Person is trustee of the trust. Read SEC document |
| May 14, 2024 Filed May 16, 2024 23:52 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 2,884 | $9.01 | $25,972.73 |
DisclosureSEC source: 0001415889-24-013388 · form4-05162024_110547.xml · nonDerivative · entry 3 Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 Disclosed balance after: 1,795,615 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F4 · price: The weighted average sale price for the transaction report was $9.0058,and the range of prices were between $9.00 and $9.06. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares old at each separate price will be provided. F5 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of the trust. Read SEC document |
| May 14, 2024 Filed May 16, 2024 23:52 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 2,873 | $9.01 | $25,881.13 |
DisclosureSEC source: 0001415889-24-013388 · form4-05162024_110547.xml · nonDerivative · entry 2 Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020 Disclosed balance after: 1,644,574 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F2 · price: The weighted average sale price for the transaction report was $9.0084,and the range of prices were between $9.00 and $9.06. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares old at each separate price will be provided. F3 · ownership.nature: The Reporting Person is trustee of the trust. Read SEC document |
| May 07, 2024 Filed May 9, 2024 22:59 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 50,000 | $9.34 | $467,230.00 |
DisclosureSEC source: 0001415889-24-012771 · form4-05092024_100505.xml · nonDerivative · entry 3 Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 Disclosed balance after: 1,798,499 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F4 · price: The weighted average sales price for the transaction report was $9.3446, and the range of prices were between $9.14 and $9.50. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares old at each separate price will be provided. F5 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of the trust. Read SEC document |
| May 07, 2024 Filed May 9, 2024 22:59 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 50,000 | $9.34 | $467,135.00 |
DisclosureSEC source: 0001415889-24-012771 · form4-05092024_100505.xml · nonDerivative · entry 2 Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Richard Lowenthal Charitable Remainder UniTrust Dated January 7, 2020 Disclosed balance after: 1,596,494 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F2 · price: The weighted average sales price for the transaction report was $9.3427, and the range of prices were between $9.14 and $9.50. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares old at each separate price will be provided. F3 · ownership.nature: The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| April 23, 2024 Filed Apr 24, 2024 22:18 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (right to buy) · Derivative | 48,260 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0001415889-24-011471 · form4-04242024_100449.xml · derivative · entry 8 Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,473 Underlying: Common Stock · 48,260 shares Expires 2031-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the option vested on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date. Read SEC document |
| April 23, 2024 Filed Apr 24, 2024 22:18 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (right to buy) · Derivative | 82,733 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001415889-24-011471 · form4-04242024_100449.xml · derivative · entry 7 Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 82,733 shares Expires 2029-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the option vested on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date. Read SEC document |
| April 23, 2024 Filed Apr 24, 2024 22:18 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 48,260 | $1.44 | $69,494.40 |
DisclosureSEC source: 0001415889-24-011471 · form4-04242024_100449.xml · nonDerivative · entry 2 Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,407,847 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 23, 2024 Filed Apr 24, 2024 22:18 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 82,733 | $0.84 | $69,495.72 |
DisclosureSEC source: 0001415889-24-011471 · form4-04242024_100449.xml · nonDerivative · entry 1 Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,359,587 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 19, 2024 Filed Apr 22, 2024 23:23 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (right to buy) · Derivative | 69,444 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0001415889-24-011335 · form4-04222024_110415.xml · derivative · entry 8 Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 166,936 Underlying: Common Stock · 69,444 shares Expires 2031-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the option vested on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date. Read SEC document |
| April 19, 2024 Filed Apr 22, 2024 23:23 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (right to buy) · Derivative | 119,047 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001415889-24-011335 · form4-04222024_110415.xml · derivative · entry 7 Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 117,333 Underlying: Common Stock · 119,047 shares Expires 2029-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the option vested on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date. Read SEC document |
| April 19, 2024 Filed Apr 22, 2024 23:23 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 69,444 | $1.44 | $99,999.36 |
DisclosureSEC source: 0001415889-24-011335 · form4-04222024_110415.xml · nonDerivative · entry 3 Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 4,315,313 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 19, 2024 Filed Apr 22, 2024 23:23 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 119,047 | $0.84 | $99,999.48 |
DisclosureSEC source: 0001415889-24-011335 · form4-04222024_110415.xml · nonDerivative · entry 2 Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 4,245,869 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 16, 2024 Filed Apr 17, 2024 22:42 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 50,000 | $9.28 | $463,985.00 |
DisclosureSEC source: 0001415889-24-011056 · form4-04172024_100426.xml · nonDerivative · entry 3 Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 Disclosed balance after: 1,848,499 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F4 · price: The weighted average sales price for the transaction report was $9.2797,and the range of prices were between $9.05 and $9.47. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares old at each separate price will be provided. F5 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of the trust. Read SEC document |
| April 16, 2024 Filed Apr 17, 2024 22:42 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 50,000 | $9.28 | $464,020.00 |
DisclosureSEC source: 0001415889-24-011056 · form4-04172024_100426.xml · nonDerivative · entry 2 Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020 Disclosed balance after: 1,647,447 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F2 · price: The weighted average sales price for the transaction report was $9.2804,and the range of prices were between $9.05 and $9.46. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares old at each separate price will be provided. F3 · ownership.nature: The Reporting Person is trustee of the trust. Read SEC document |
| April 09, 2024 Filed Apr 10, 2024 21:39 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 50,000 | $9.28 | $463,850.00 |
DisclosureSEC source: 0001415889-24-010660 · form4-04102024_090450.xml · nonDerivative · entry 3 Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 Disclosed balance after: 1,898,499 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F4 · price: The weighted average sales price for the transaction report was $9.277,and the range of prices were between $9.13 and $9.91. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares old at each separate price will be provided. F5 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of the trust. Read SEC document |
| April 09, 2024 Filed Apr 10, 2024 21:39 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 50,000 | $9.28 | $463,885.00 |
DisclosureSEC source: 0001415889-24-010660 · form4-04102024_090450.xml · nonDerivative · entry 2 Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Richard Lowenthal Charitable Remainder UniTrust Dated January 7, 2020 Disclosed balance after: 1,646,494 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F2 · price: The weighted average sales price for the transaction report was $9.2777,and the range of prices were between $9.13 and $9.91. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares old at each separate price will be provided. F3 · ownership.nature: The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 25, 2024 Filed Mar 26, 2024 22:47 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 47,632 | $9.12 | $434,575.32 |
DisclosureSEC source: 0001415889-24-009152 · form4-03262024_100316.xml · nonDerivative · entry 5 Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 Disclosed balance after: 1,948,499 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F7 · price: The weighted average sales price for the transaction report was $9.1236,and the range of prices were between $9.03 and $9.36. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares old at each separate price will be provided. F5 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of the trust. Read SEC document |
| March 25, 2024 Filed Mar 26, 2024 22:47 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 47,635 | $9.12 | $434,612.21 |
DisclosureSEC source: 0001415889-24-009152 · form4-03262024_100316.xml · nonDerivative · entry 4 Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020 Disclosed balance after: 1,697,447 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F6 · price: The weighted average sales price for the transaction report was $9.1238,and the range of prices were between $9.03 and $9.36. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares old at each separate price will be provided. F3 · ownership.nature: The Reporting Person is trustee of the trust. Read SEC document |
| March 22, 2024 Filed Mar 26, 2024 22:47 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 1,326 | $9.01 | $11,951.50 |
DisclosureSEC source: 0001415889-24-009152 · form4-03262024_100316.xml · nonDerivative · entry 3 Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 Disclosed balance after: 1,996,131 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F4 · price: The weighted average sales price for the transaction report was $9.0132,and the range of prices were between $9.00 and $9.07. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares old at each separate price will be provided. F5 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of the trust. Read SEC document |
| March 22, 2024 Filed Mar 26, 2024 22:47 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 1,017 | $9.03 | $9,183.31 |
DisclosureSEC source: 0001415889-24-009152 · form4-03262024_100316.xml · nonDerivative · entry 2 Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020 Disclosed balance after: 1,745,082 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F2 · price: The weighted average sales price for the transaction report was $9.0298,and the range of prices were between $9.00 and $9.06. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares old at each separate price will be provided. F3 · ownership.nature: The Reporting Person is trustee of the trust. Read SEC document |
| March 21, 2024 Filed Mar 22, 2024 01:50 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 100 | $9.00 | $900.00 |
DisclosureSEC source: 0001415889-24-008900 · form4-03222024_010325.xml · nonDerivative · entry 4 Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 Disclosed balance after: 1,997,457 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F5 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of the trust. Read SEC document |
| March 21, 2024 Filed Mar 22, 2024 01:50 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 372 | $9.00 | $3,348.00 |
DisclosureSEC source: 0001415889-24-008900 · form4-03222024_010325.xml · nonDerivative · entry 3 Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020 Disclosed balance after: 1,746,099 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F3 · ownership.nature: The Reporting Person is trustee of the trust. Read SEC document |
| March 19, 2024 Filed Mar 22, 2024 01:50 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 942 | $9.04 | $8,513.42 |
DisclosureSEC source: 0001415889-24-008900 · form4-03222024_010325.xml · nonDerivative · entry 2 Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 Disclosed balance after: 1,997,557 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F4 · price: The weighted average sales price for the transaction report was $9.0376,and the range of prices were between $9.02 and $9.08. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares old at each separate price will be provided. F5 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of the trust. Read SEC document |
| March 19, 2024 Filed Mar 22, 2024 01:50 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 976 | $9.03 | $8,810.64 |
DisclosureSEC source: 0001415889-24-008900 · form4-03222024_010325.xml · nonDerivative · entry 1 Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020 Disclosed balance after: 1,746,471 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F2 · price: The weighted average sales price for the transaction report was $9.0273,and the range of prices were between $9.01 and $9.09. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares old at each separate price will be provided. F3 · ownership.nature: The Reporting Person is trustee of the trust. Read SEC document |
| March 15, 2024 Filed Mar 15, 2024 23:52 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 48,461 | $9.14 | $442,996.54 |
DisclosureSEC source: 0001415889-24-008167 · form4-03152024_110356.xml · nonDerivative · entry 7 Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 Disclosed balance after: 1,998,499 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F5 · price: The weighted average sale price for the transaction reported was $9.1413, and the range of prices were between $9.02 and $9.22. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F3 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of the trust. Read SEC document |
| March 15, 2024 Filed Mar 15, 2024 23:52 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 48,295 | $9.14 | $441,488.74 |
DisclosureSEC source: 0001415889-24-008167 · form4-03152024_110356.xml · nonDerivative · entry 6 Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020 Disclosed balance after: 1,696,494 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F4 · price: The weighted average sale price for the transaction reported was $9.1415, and the range of prices were between $9.01 and $9.22. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided F2 · ownership.nature: The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 14, 2024 Filed Mar 15, 2024 23:52 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 239 | $9.00 | $2,151.00 |
DisclosureSEC source: 0001415889-24-008167 · form4-03152024_110356.xml · nonDerivative · entry 5 Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 Disclosed balance after: 2,046,960 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F3 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of the trust. Read SEC document |
| March 14, 2024 Filed Mar 15, 2024 23:52 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 205 | $9.00 | $1,845.00 |
DisclosureSEC source: 0001415889-24-008167 · form4-03152024_110356.xml · nonDerivative · entry 4 Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020 Disclosed balance after: 1,744,789 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F2 · ownership.nature: The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 23:52 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 1,300 | $9.00 | $11,700.00 |
DisclosureSEC source: 0001415889-24-008167 · form4-03152024_110356.xml · nonDerivative · entry 3 Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 Disclosed balance after: 2,047,199 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F3 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of the trust. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 23:52 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 1,500 | $9.00 | $13,500.00 |
DisclosureSEC source: 0001415889-24-008167 · form4-03152024_110356.xml · nonDerivative · entry 2 Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020 Disclosed balance after: 1,744,994 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F2 · ownership.nature: The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| February 29, 2024 Filed Mar 2, 2024 01:21 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 1,000 | $9.02 | $9,019.00 |
DisclosureSEC source: 0001415889-24-006188 · form4-03022024_010328.xml · nonDerivative · entry 4 Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020 Disclosed balance after: 1,747,447 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F6 · price: The weighted average sale price for the transaction reported was $9.0190, and the range of prices were between $9.00 and $9.10. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F7 · ownership.nature: The Reporting Person is trustee of the trust. Read SEC document |
| February 29, 2024 Filed Mar 2, 2024 01:21 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 1,982 | $9.01 | $17,866.54 |
DisclosureSEC source: 0001415889-24-006188 · form4-03022024_010328.xml · nonDerivative · entry 3 Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 Disclosed balance after: 2,048,499 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F4 · price: The weighted average sale price for the transaction reported was $9.0144, and the range of prices were between $9.00 and $9.10. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F5 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of the trust. Read SEC document |
| February 29, 2024 Filed Mar 2, 2024 01:21 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 800 | $9.02 | $7,215.04 |
DisclosureSEC source: 0001415889-24-006188 · form4-03022024_010328.xml · nonDerivative · entry 2 Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020 Disclosed balance after: 1,746,494 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F2 · price: The weighted average sale price for the transaction reported was $9.0188, and the range of prices were between $9.00 and $9.10. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F3 · ownership.nature: The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| February 28, 2024 Filed Feb 29, 2024 02:08 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 24,303 | $9.02 | $219,225.21 |
DisclosureSEC source: 0001415889-24-005791 · form4-02292024_020243.xml · nonDerivative · entry 7 Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020 Disclosed balance after: 1,748,447 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F7 · price: The weighted average sale price for the transaction reported was $9.0205, and the range of prices were between $9.00 and $9.17. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F4 · ownership.nature: The Reporting Person is trustee of the trust. Read SEC document |
| February 28, 2024 Filed Feb 29, 2024 02:08 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 49,019 | $9.02 | $442,210.20 |
DisclosureSEC source: 0001415889-24-005791 · form4-02292024_020243.xml · nonDerivative · entry 6 Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 Disclosed balance after: 2,050,481 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F6 · price: The weighted average sale price for the transaction reported was $9.0212, and the range of prices were between $9.00 and $9.19. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F3 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of the trust. Read SEC document |
| February 28, 2024 Filed Feb 29, 2024 02:08 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 25,456 | $9.02 | $229,625.85 |
DisclosureSEC source: 0001415889-24-005791 · form4-02292024_020243.xml · nonDerivative · entry 5 Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020 Disclosed balance after: 1,747,294 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F5 · price: The weighted average sale price for the transaction reported was $9.0205, and the range of prices were between $9.00 and $9.19. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F2 · ownership.nature: The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| February 26, 2024 Filed Feb 29, 2024 02:08 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 100 | $9.01 | $901.00 |
DisclosureSEC source: 0001415889-24-005791 · form4-02292024_020243.xml · nonDerivative · entry 4 Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Sarina Tanimoto Charitable Remainder Unitrust Dated January 7, 2020 Disclosed balance after: 1,772,750 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F4 · ownership.nature: The Reporting Person is trustee of the trust. Read SEC document |
| February 26, 2024 Filed Feb 29, 2024 02:08 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 500 | $9.01 | $4,505.00 |
DisclosureSEC source: 0001415889-24-005791 · form4-02292024_020243.xml · nonDerivative · entry 3 Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 Disclosed balance after: 2,099,500 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F3 · ownership.nature: The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of the trust. Read SEC document |
| February 26, 2024 Filed Feb 29, 2024 02:08 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 100 | $9.01 | $901.00 |
DisclosureSEC source: 0001415889-24-005791 · form4-02292024_020243.xml · nonDerivative · entry 2 Tanimoto Sarina · CIK 0001951291 · CHIEF MEDICAL OFFICER · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020 Disclosed balance after: 1,772,750 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. F2 · ownership.nature: The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:45 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock option (right to buy) · Derivative | 880,000 | $0.00 Strike: $5.58 | $0.00 |
DisclosureSEC source: 0001209191-24-000815 · doc4.xml · derivative · entry 8 Tanimoto Sarina · CIK 0001951291 · Chief Medical Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By spouse Disclosed balance after: 880,000 Underlying: Common Stock · 880,000 shares Expires 2034-01-01 F5 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 1, 2025, and the remaining shares will vest monthly thereafter over three years. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:45 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock option (right to buy) · Derivative | 300,000 | $0.00 Strike: $5.58 | $0.00 |
DisclosureSEC source: 0001209191-24-000815 · doc4.xml · derivative · entry 7 Tanimoto Sarina · CIK 0001951291 · Chief Medical Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2034-01-01 F5 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 1, 2025, and the remaining shares will vest monthly thereafter over three years. Read SEC document |
| May 17, 2023 Filed Jan 4, 2024 21:45 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GiftCommon Stock | 1,050,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-000815 · doc4.xml · nonDerivative · entry 4 Tanimoto Sarina · CIK 0001951291 · Chief Medical Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 Disclosed balance after: 2,100,000 F1 · ownership.nature: These shares are held in a trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of the trust. Read SEC document |
| May 17, 2023 Filed Jan 4, 2024 21:45 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GiftCommon Stock | 1,050,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-000815 · doc4.xml · nonDerivative · entry 3 Tanimoto Sarina · CIK 0001951291 · Chief Medical Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By spouse Disclosed balance after: 4,126,822 F2 · balance_after: The Form 4 filed November 10, 2022 inadvertently omitted 849,968 shares indirectly owned by the Reporting Person. The omitted shares are directly owned by the Reporting Person's spouse and were properly reported on his Form 4 filed November 10, 2022. The amount listed in Column 5 has been adjusted to reflect the correct holdings after giving effect to the May 17, 2023 gift transaction. Read SEC document |
| May 17, 2023 Filed Jan 4, 2024 21:45 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GiftCommon Stock | 1,050,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-000815 · doc4.xml · nonDerivative · entry 2 Tanimoto Sarina · CIK 0001951291 · Chief Medical Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 Disclosed balance after: 1,050,000 F1 · ownership.nature: These shares are held in a trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of the trust. Read SEC document |
| May 17, 2023 Filed Jan 4, 2024 21:45 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GiftCommon Stock | 1,050,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-000815 · doc4.xml · nonDerivative · entry 1 Tanimoto Sarina · CIK 0001951291 · Chief Medical Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,276,854 Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 22:00 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock option (right to buy) · Derivative | 1,100,000 | $0.00 Strike: $8.42 | $0.00 |
DisclosureSEC source: 0001209191-23-001927 · doc4.xml · derivative · entry 2 Tanimoto Sarina · CIK 0001951291 · Chief Medical Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 1,100,000 Underlying: Common Stock · 1,100,000 shares Expires 2033-01-02 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2024, and the remaining shares will vest monthly thereafter over three years. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 22:00 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock option (right to buy) · Derivative | 350,000 | $0.00 Strike: $8.42 | $0.00 |
DisclosureSEC source: 0001209191-23-001927 · doc4.xml · derivative · entry 1 Tanimoto Sarina · CIK 0001951291 · Chief Medical Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2033-01-02 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2024, and the remaining shares will vest monthly thereafter over three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.